We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our Portfolio Our portfolio is principally focused on our lead product candidate, Niyad (nafamostat mesylate), for use as a regional anticoagulant during continuous renal replacement therapy, or CRRT.
Phase 3 · ActiveModality: lyophilized formulation of nafamostat
Target serine proteases
Partnerships CorMedix: right of first negotiation on acquisition of the company for 60 days after public announcement of NEPHRO CRRT topline (terminates Dec 31, 2027, or on study termination).
Indications
Regional anticoagulant for the dialysis circuit during continuous renal replacement therapy (CRRT) in acute kidney injury(Phase 3)
Regional anticoagulant for the dialysis circuit in intermittent hemodialysis (CKD)(Stage not disclosed)
Catalysts
— 2026
Status note Lead candidate. NEPHRO CRRT (Nafamostat Efficacy in Phase 3 Registrational CRRT Study): IDE-approved, double-blind, up to 14 US ICUs, 70 adult patients; 35 patients enrolled as of Mar 2026. PMA submission planned on trial completion. FDA Breakthrough Device Designation.
LTX-608
Stage not disclosed · ActiveModality: nafamostat formulation for direct IV infusion
Target serine proteases
Indications
Disseminated intravascular coagulation (DIC)(Stage not disclosed)
Acute respiratory distress syndrome (ARDS)(Stage not disclosed)
Acute pancreatitis(Stage not disclosed)
Anti-viral treatment(Stage not disclosed)
Status note Nafamostat formulation for direct IV infusion that the company may develop for one or more listed indications.
Fedsyra
Stage not disclosed · ActiveModality: pre-filled syringe
Aliases ephedrine pre-filled syringe
Partnerships Laboratoire Aguettant: US development/commercialization license (Jul 2021); agreement being evaluated for potential termination.
Status note Product candidates being evaluated for discontinuation given the competitive environment.
Phenylephrine PFS
Stage not disclosed · ActiveModality: pre-filled syringe
Aliases phenylephrine pre-filled syringe
Partnerships Laboratoire Aguettant: US development/commercialization license (Jul 2021); agreement being evaluated for potential termination.
Status note Product candidates being evaluated for discontinuation given the competitive environment.
Per-asset detail extracted from the 10-Q filed 2026-08-12. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.